How effective is BCG therapy for recurrent bladder cancer?

Question

Hello doctor,

My father is 67 years old. He underwent surgery for bladder cancer six months ago and has recently experienced a recurrence. The doctor has suggested intravesical BCG therapy, but we are concerned about its side effects and success rate. How effective is BCG therapy for recurrent bladder cancer, and at what stage do doctors consider removing the bladder?

Kindly advise.

Answer 1

Hello,

Welcome to icliniq.com.

I understand the concern.

I am very sorry to hear about your father’s recurrence. Facing bladder cancer again can be very frightening, and it is completely natural to have concerns about treatment and outcomes.

Intravesical bacillus calmette-guérin (BCG) therapy is one of the most effective treatments for non-muscle-invasive bladder cancer (NMIBC). It is especially recommended for high-risk tumors that recur after surgery. BCG is a live attenuated strain of Mycobacterium bovis that stimulates the immune system to attack cancer cells present in the lining of the bladder. It significantly reduces the risk of further recurrence and progression in many patients.

However, BCG therapy may cause side effects. The most common effects include bladder irritation, burning during urination, frequent urination, mild fever, fatigue, and flu-like symptoms. In rare cases, a more serious systemic infection can occur, particularly in elderly patients or those with weakened immunity. Most side effects are temporary and manageable under medical supervision.

The success rate of BCG therapy depends on several factors, including tumor grade, tumor size, number of recurrences, and overall health condition. Studies show that many patients with high-risk NMIBC achieve remission for several years. However, maintenance therapy may be required, and some patients may need additional treatment if recurrence persists.

Doctors consider radical cystectomy (complete removal of the urinary bladder) in the following situations:

When the cancer invades the muscle layer of the bladder (muscle-invasive bladder cancer).
When high-grade tumors persist despite adequate BCG therapy.
When there are multiple recurrences even after proper intravesical treatment.
When there are aggressive pathological features suggesting a high risk of progression.

Regular follow-up with cystoscopy, imaging studies, and urine cytology is essential to detect recurrence early. Treatment decisions are individualized based on tumor characteristics, response to therapy, and the patient’s overall medical condition.

Although this is a stressful time, BCG therapy remains a highly effective treatment option for recurrent non-muscle-invasive bladder cancer. With close monitoring and timely intervention, many patients are able to maintain good disease control and quality of life.

I hope you are satisfied with my answer. For further queries, you can consult me at iCliniq.

Thank you.